15 minutes
For years, patients and patient advocacy groups have expressed a disconnect between their firsthand experiences with their disease and the healthcare industry’s understanding of their disease. As the healthcare industry bases day-to-day care or new treatments on its understanding, real patient needs are often unmet: new drugs are developed with incremental improvements or ignore symptoms that impact quality of life. To stop this cycle and deliver transformational products, we must bring together physicians, regulators, scientists, and patients to interact across the drug discovery process.


Domi Stickens - Sr. Director, Head of Translational Sciences at Mitobridge, Inc., an Astellas Company